Prognostic impact of <i>TP53</i> mutation in newly diagnosed diffuse large B‐cell lymphoma patients treated in the FIL‐DLCL04 trialAnnalisa Chiappella, Fary Diop, Claudio Agostinelli et al.|British Journal of Haematology|2021Cited by 39
Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future DirectionsC. Savelli, Mattia Novo, Marco Cerrano et al.|Cancers|2023Cited by 12
Nivolumab PD-1 Blockade as Bridge to Allogeneic Stem Cell Transplant (HSCT) in Gray-Zone Lymphoma: Case ReportMaura Nicolosi, Barbara Botto, Chiara Maria Dellacasa et al.|Archives of Clinical and Medical Case Reports|2023Cited by 0
447 | POLATUZUMAB‐CONTAINING REGIMENS AS BRIDGE TO CAR‐T: INSIGHTS FROM THE ITALIAN CAR T‐SIE STUDYGiulia Gabrielli, P. L. Zinzani, Benedetta Casadei et al.|Hematological Oncology|2025Cited by 0
Polatuzumab vedotin–containing regimens as bridge to CART: analysis from the CART-SIE studyGiulia Gabrielli, Pier Luigi Zinzani, Beatrice Casadei et al.|Blood Advances|2026Cited by 0